数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
Medicare annual wellness visits (AWVs) may facilitate early diagnosis of Alzheimer disease and related dementias (ADRDs).
方法
This retrospective cohort study used 100% Medicare data for beneficiaries with ADRDs diagnosed from January 1 to December 31, 2018, who had continuous enrollment in Medicare Parts A, B, and D, from 3 years before to 1 year after the index date (January 1, 2018), excluding those enrolled in health maintenance organizations and with prior dementia medication prescriptions.；In this cohort of 799 268 Medicare beneficiaries with ADRDs (mean [SD] age, 82.3 [7.9] years; 64.5% female), 60.8% received no AWVs, 19.2% received 1 AWV, 12.9% received 2 AWVs, and 7.2% received 3 or more AWVs.；In this cohort study of Medicare beneficiaries with ADRD, an increasing number of AWVs received was associated…
核心结论
To examine the association between incident AWVs and new dementia medication prescriptions.；Data analysis was performed from August 2025 to August 2026.；Number of AWVs received in the 3 years before the index date (0, 1, 2, or ≥3). ‖ 结论：These findings underscore the important role that AWVs may have in increasing the prescribing of medications that help manage symptoms of ADRD and suggest AWVs are essential to support quality dementia care (eg, symptom management) and advance care planning for future living arrangements.
局限
未能获取全文，具体设计细节、失访与统计学处理无法核验。
对本项目的价值
★★★★☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。顶刊证据。
原文题录
- 英文标题：Annual Wellness Visits and New Dementia Medication Prescriptions Among US Medicare Beneficiaries.
- 期刊与标识：JAMA Netw Open · PMID 42944685 · DOI 10.1001/jamanetworkopen.2026.40804**
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。